期刊文献+

托法替尼的结构鉴定与构象分析 被引量:4

Structure Determination and Conformational Analysis of Tofacitinib
原文传递
导出
摘要 目的鉴定合成的托法替尼的化学结构,并对其构象进行分析。方法用DMSO-d6作溶剂,通过测试该合成样品的~1H-NMR、~1H-NMR(DMSO-d6+D_2O)、^(13)C-NMR(包括常温、高温60℃、高温120℃的图谱)、~1H-~1H COSY、DEPT、HSQC、HMBC图谱及其关键中间体的常温^(13)C-NMR图谱,参照文献与专著,鉴定合成的托法替尼的化学结构,并分析其构象。结果确证了合成的托法替尼的化学结构。其常温^(13)C-NMR图谱中,大多数信号出现裂分,升温到120℃,裂分信号合并,推导在常温下,因为围绕酰胺键的旋转受阻,托法替尼在DMSO-d6溶液中以2种构象存在。结论合成的托法替尼结构正确,且常温下在DMSO-d6溶液中以2种构象存在。 OBJECTIVE To investigate the structure and conformation of synthesized Tofacitinib. METHODS The 1H-NMR,1H-NMR(DMSO-d6+D2O),13C-NMR(at room and elevated temperature of 60 and 120 ℃), 1H-1H COSY, DEPT, HSQC,HMBC spectra of Tofacitinib and 13C-NMR of its key intermediate at room temperature were recorded in DMSO-d6. Based on the related literature, monograph and the 13C-NMR comparison of Tofacitinib and its key intermediate, the structure and conformation analysis of synthesized Tofacitinib in DMSO-d6 were carried out. RESULTS The structure of synthesized Tofacitinib was determined on the basis of these spectral data. Most of the signals of Tofacitinib in 13C-NMR spectrum at room temperature were split while these split signals were merged when the temperature was increased to 120 ℃. It maight have two conformations in DMSO-d6 at room temperature due to the restricted rotation about the carbon-nitrogen bond of the amide group.CONCLUSION The structure of synthesized Tofacitinib is confirmed and it may have two conformations in DMSO-d6 at room temperature.
作者 张霞 章国龙 ZHANG Xia;ZHANG Guolong(Huadong Medicine Group Pharmaceutical Research Institute Co.,Ltd.,Hangzhou 310011,China)
出处 《中国现代应用药学》 CAS CSCD 北大核心 2019年第5期542-544,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 托法替尼 构象 核磁共振 关键中间体 受阻旋转 Tofacitinib conformation nuclear magnetic resonance key intermediate restricted rotation
  • 相关文献

参考文献6

二级参考文献77

  • 1姜凤超,周晓.羟苯磺酸钙的合成[J].中国医药工业杂志,1994,25(9):389-390. 被引量:7
  • 2徐文方,于遐,顾笑梅,张世军,袁玉梅.微循环营养药二羟苯磺酸钙的合成[J].山东医科大学学报,1996,34(4):346-348. 被引量:6
  • 3Gabriel K.. Contemporary Cardiology: Cardiac Drug Therapy(7th Ed.)[M], Totowa: Humana Press Inc., 2007.
  • 4Friedrich E. B., Teo KK., B?hm M.. Clin. Res. Cardiol.[J]..2006, 95:61-67.
  • 5Pitt B.. Cardiovasc. Drug. Ther.[J], 2001, 15: 103-105.
  • 6Dutrey-Dupagne C., Girard A., Ulmann A., Elghozi J. L.. Clin. Auton. Res.[J], 1991, 1(4): 303-307.
  • 7Diaz A., Ducharme A. Vasc. Health and Risk Manag.[J]..2008, 4(6):1147-1158.
  • 8Aliev A. E., Courtier-Murias D.. J. Phys. Chem. B[J], 2007, 111: 14034-14042.
  • 9Belostotskii A. M.. JOrg. Chem.[J]..2008, 73:5723-5731.
  • 10Munoz M. A., Joseph-Nathan P. Magn. Reson. Chem. [J]..2010, 48:458-463.

共引文献21

同被引文献53

引证文献4

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部